AID researchers possess a strong translational record in the field of vaccinology, notably in the development of new vaccines, vaccine technologies, needle-less delivery systems, novel adjuvants and vaccine formulations. Research on defining immune responses induced by new and emerging vaccines as well as post-vaccine surveillance and tools for government decision making complete the end-to-end capabilities of the AID network. Moreover, our experts develop procedures and policies for preventing hospital-acquired infections, which pose a major health concern especially when associated with antimicrobial resistance.
- Vaccines and adjuvants
- Vaccine formulation and delivery technologies
- Bioengineering solutions for delivery, surface coating, sampling
- Characterisation of vaccine-induced immune responses
- Post-vaccine surveillance and correlates of protection
- Clinical practices for preventing hospital-acquired infection
Impact:
- UQ molecular clamp vaccine technology platform commercialised through spin-off Vicebio, acquired by Sanofi in 2025
- Key expertise and research for Translational Sciences Hub, a collaborative initiative by Sanofi, UQ, Griffith University and the QLD Government
- Key expertise and capabilities for QLD-Emory Vaccine Centre (QEVC)
- mRNA capabilities for partnerships with major pharma
- Field surveillance and decision support tools for governments